サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1355395

世界の短時間作用型EPO製剤市場：考察と予測 (2029年まで)

Global Short-acting EPO Drugs Market Insights, Forecast to 2029
出版日: | 発行: QYResearch | ページ情報: 英文 111 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
世界の短時間作用型EPO製剤市場：考察と予測 (2029年まで)
出版日: 2023年10月04日
発行: QYResearch
ページ情報: 英文 111 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、短時間作用型EPO製剤 (Short-acting EPO Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 短時間作用型EPO製剤の製品概要
  • 市場：タイプ別
    • 世界の短時間作用型EPO製剤の市場規模成長率：タイプ別, 2018 VS 2022 VS 2029
    • Epoetin-alfa
    • Epoetin-beta
    • Darbepoetin-alfa
    • Others
  • 市場：用途別
    • 世界の短時間作用型EPO製剤の市場規模成長率：用途別, 2018 VS 2022 VS 2029
    • Anemia
    • Kidney Disorders
    • Others
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の短時間作用型EPO製剤売上予測・予想 2018-2029
  • 世界の短時間作用型EPO製剤の収益：地域別
    • 世界の短時間作用型EPO製剤の収益：地域別: 2018 VS 2022 VS 2029
    • 世界の短時間作用型EPO製剤の収益：地域別 (2018-2023)
    • 世界の短時間作用型EPO製剤の収益：地域別 (2024-2029)
    • 世界の短時間作用型EPO製剤の収益市場シェア 地域別 (2018-2029)
  • 世界の短時間作用型EPO製剤売上予測・予想 2018-2029
  • 世界の短時間作用型EPO製剤の販売：地域別
    • 世界の短時間作用型EPO製剤の販売：地域別: 2018 VS 2022 VS 2029
    • 世界の短時間作用型EPO製剤の販売：地域別 (2018-2023)
    • 世界の短時間作用型EPO製剤の販売：地域別 (2024-2029)
    • 世界の短時間作用型EPO製剤の販売市場シェア 地域別 (2018-2029)
  • 米国・カナダ
  • 欧州
  • 中国
  • アジア（中国を除く）
  • 中東, アフリカ ・ラテンアメリカ

第3章 競合：企業別

  • 世界の短時間作用型EPO製剤の販売：企業別
    • 世界の短時間作用型EPO製剤の販売：企業別 (2018-2023)
    • 世界の短時間作用型EPO製剤の販売市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 短時間作用型EPO製剤 in 2022
  • 世界の短時間作用型EPO製剤の収益：企業別
    • 世界の短時間作用型EPO製剤の収益：企業別 (2018-2023)
    • 世界の短時間作用型EPO製剤の収益市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 短時間作用型EPO製剤の収益 2022
  • 世界の主要企業 短時間作用型EPO製剤, 業界ランキング, 2021 VS 2022 VS 2023
  • 世界の短時間作用型EPO製剤の販売価格：企業別
  • 競合情勢の分析
    • 企業の市場集中度 (CR5 and HHI)
    • 世界の短時間作用型EPO製剤の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 世界の主要メーカー 短時間作用型EPO製剤, 製造拠点分布と本社
  • 世界の主要メーカー 短時間作用型EPO製剤, 提供製品と用途
  • 世界の主要メーカー 短時間作用型EPO製剤, 業界参入時期
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の短時間作用型EPO製剤の販売：タイプ別
    • 世界の短時間作用型EPO製剤の販売実績：タイプ別 (2018-2023)
    • 世界の短時間作用型EPO製剤の販売予測：タイプ別 (2024-2029)
    • 世界の短時間作用型EPO製剤の販売市場シェア：タイプ別 (2018-2029)
  • 世界の短時間作用型EPO製剤 収益：タイプ別
    • 世界の短時間作用型EPO製剤の収益実績：タイプ別 (2018-2023)
    • 世界の短時間作用型EPO製剤の収益予測：タイプ別 (2024-2029)
    • 世界の短時間作用型EPO製剤の収益市場シェア：タイプ別 (2018-2029)
  • 世界の短時間作用型EPO製剤の価格：タイプ別
    • 世界の短時間作用型EPO製剤の価格：タイプ別 (2018-2023)
    • 世界の短時間作用型EPO製剤の価格予測：タイプ別 (2024-2029)

第5章 市場規模：用途別

  • 世界の短時間作用型EPO製剤の販売：用途別
    • 世界の短時間作用型EPO製剤の販売実績：用途別 (2018-2023)
    • 世界の短時間作用型EPO製剤の販売予測：用途別 (2024-2029)
    • 世界の短時間作用型EPO製剤の販売市場シェア：用途別 (2018-2029)
  • 世界の短時間作用型EPO製剤の収益：用途別
    • 世界の短時間作用型EPO製剤の収益実績：用途別 (2018-2023)
    • 世界の短時間作用型EPO製剤の収益予測：用途別 (2024-2029)
    • 世界の短時間作用型EPO製剤の収益市場シェア：用途別 (2018-2029)
  • 世界の短時間作用型EPO製剤の価格：用途別
    • 世界の短時間作用型EPO製剤の価格：用途別 (2018-2023)
    • 世界の短時間作用型EPO製剤の価格予測：用途別 (2024-2029)

第6章 米国・カナダ

  • 米国・カナダ 短時間作用型EPO製剤 市場規模：タイプ別
    • 米国・カナダ 短時間作用型EPO製剤の販売：タイプ別 (2018-2029)
    • 米国・カナダ 短時間作用型EPO製剤 収益：タイプ別 (2018-2029)
  • 米国・カナダ 短時間作用型EPO製剤 市場規模：用途別
    • 米国・カナダ 短時間作用型EPO製剤の販売：用途別 (2018-2029)
    • 米国・カナダ 短時間作用型EPO製剤の収益：用途別 (2018-2029)
  • 米国・カナダ 短時間作用型EPO製剤 市場規模：国別
    • 米国・カナダ 短時間作用型EPO製剤の収益：国別: 2018 VS 2022 VS 2029
    • 米国・カナダ 短時間作用型EPO製剤の販売：国別 (2018-2029)
    • 米国・カナダ 短時間作用型EPO製剤の収益：国別 (2018-2029)
    • US
    • カナダ

第7章 欧州

  • 欧州の短時間作用型EPO製剤 市場規模：タイプ別
    • 欧州の短時間作用型EPO製剤の販売：タイプ別 (2018-2029)
    • 欧州の短時間作用型EPO製剤 収益：タイプ別 (2018-2029)
  • 欧州の短時間作用型EPO製剤 市場規模：用途別
    • 欧州の短時間作用型EPO製剤の販売：用途別 (2018-2029)
    • 欧州の短時間作用型EPO製剤の収益：用途別 (2018-2029)
  • 欧州の短時間作用型EPO製剤 市場規模：国別
    • 欧州の短時間作用型EPO製剤の収益：国別: 2018 VS 2022 VS 2029
    • 欧州の短時間作用型EPO製剤の販売：国別 (2018-2029)
    • 欧州の短時間作用型EPO製剤の収益：国別 (2018-2029)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 中国

  • 中国の短時間作用型EPO製剤 市場規模
    • 中国の短時間作用型EPO製剤 売上 (2018-2029)
    • 中国の短時間作用型EPO製剤 収益 (2018-2029)
  • 中国の短時間作用型EPO製剤 市場規模：用途別
    • 中国の短時間作用型EPO製剤の販売：用途別 (2018-2029)
    • 中国の短時間作用型EPO製剤の収益：用途別 (2018-2029)

第9章 アジア（中国を除く）

  • アジア地域 短時間作用型EPO製剤 市場規模：タイプ別
    • アジア地域 短時間作用型EPO製剤の販売：タイプ別 (2018-2029)
    • アジア地域 短時間作用型EPO製剤 収益：タイプ別 (2018-2029)
  • アジア地域 短時間作用型EPO製剤 市場規模：用途別
    • アジア地域 短時間作用型EPO製剤の販売：用途別 (2018-2029)
    • アジア地域 短時間作用型EPO製剤の収益：用途別 (2018-2029)
  • アジア地域 短時間作用型EPO製剤の販売：地域別
    • アジア地域 短時間作用型EPO製剤の収益：地域別: 2018 VS 2022 VS 2029
    • アジア地域 短時間作用型EPO製剤の収益：地域別 (2018-2029)
    • アジア地域 短時間作用型EPO製剤の販売：地域別 (2018-2029)
    • 日本
    • 韓国
    • 台湾
    • 東南アジア
    • インド

第10章 中東, アフリカ ・ラテンアメリカ

  • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤 市場規模：タイプ別
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の販売：タイプ別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤 収益：タイプ別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤 市場規模：用途別
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の販売：用途別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の収益：用途別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の販売：国別
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の収益：国別: 2018 VS 2022 VS 2029
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の収益：国別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの短時間作用型EPO製剤の販売：国別 (2018-2029)
    • ブラジル
    • メキシコ
    • トルコ
    • イスラエル
    • 湾岸協力理事会諸国

第11章 企業プロファイル

  • Amgen
  • Johnson & Johnson
  • Roche
  • Kyowa Kirin
  • LG Chem
  • Daewoong Pharmaceutical
  • Wockhardt
  • CJ Healthcare
  • 3SBio
  • Kexing Biopharm
  • Harbin Pharmaceutical Group
  • Beijing Four Rings Bio-Pharmaceutical

第12章 業界チェーンと販売チャネルの分析

  • 短時間作用型EPO製剤 業界チェーン分析
  • 短時間作用型EPO製剤 主要原材料
    • 主要原材料
    • 原材料の主要サプライヤー
  • 短時間作用型EPO製剤 生産形態とプロセス
  • 短時間作用型EPO製剤 販売およびマーケティング
    • 短時間作用型EPO製剤 販売チャネル
    • 短時間作用型EPO製剤 卸業者
  • 短時間作用型EPO製剤 顧客

第13章 市場動向

  • 短時間作用型EPO製剤 業界動向
  • 短時間作用型EPO製剤 市場の促進要因
  • 短時間作用型EPO製剤 市場の課題
  • 短時間作用型EPO製剤 市場の抑制要因

第14章 主な調査結果 世界の短時間作用型EPO製剤の主な市場調査結果

第15章 付録

図表

List of Tables

  • Table 1. Global Short-acting EPO Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 2. Major Manufacturers of Epoetin-alfa
  • Table 3. Major Manufacturers of Epoetin-beta
  • Table 4. Major Manufacturers of Darbepoetin-alfa
  • Table 5. Major Manufacturers of Others
  • Table 6. Global Short-acting EPO Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 7. Global Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 8. Global Short-acting EPO Drugs Revenue by Region (2018-2023) & (US$ Million)
  • Table 9. Global Short-acting EPO Drugs Revenue by Region (2024-2029) & (US$ Million)
  • Table 10. Global Short-acting EPO Drugs Revenue Market Share by Region (2018-2023)
  • Table 11. Global Short-acting EPO Drugs Revenue Market Share by Region (2024-2029)
  • Table 12. Global Short-acting EPO Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 13. Global Short-acting EPO Drugs Sales by Region (2018-2023) & (K Units)
  • Table 14. Global Short-acting EPO Drugs Sales by Region (2024-2029) & (K Units)
  • Table 15. Global Short-acting EPO Drugs Sales Market Share by Region (2018-2023)
  • Table 16. Global Short-acting EPO Drugs Sales Market Share by Region (2024-2029)
  • Table 17. Global Short-acting EPO Drugs Sales by Manufacturers (2018-2023) & (K Units)
  • Table 18. Global Short-acting EPO Drugs Sales Share by Manufacturers (2018-2023)
  • Table 19. Global Short-acting EPO Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
  • Table 20. Global Short-acting EPO Drugs Revenue Share by Manufacturers (2018-2023)
  • Table 21. Global Key Players of Short-acting EPO Drugs, Industry Ranking, 2021 VS 2022 VS 2023
  • Table 22. Short-acting EPO Drugs Price by Manufacturers 2018-2023 (US$/Unit)
  • Table 23. Global Short-acting EPO Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 24. Global Short-acting EPO Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting EPO Drugs as of 2022)
  • Table 25. Global Key Manufacturers of Short-acting EPO Drugs, Manufacturing Base Distribution and Headquarters
  • Table 26. Global Key Manufacturers of Short-acting EPO Drugs, Product Offered and Application
  • Table 27. Global Key Manufacturers of Short-acting EPO Drugs, Date of Enter into This Industry
  • Table 28. Mergers & Acquisitions, Expansion Plans
  • Table 29. Global Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
  • Table 30. Global Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
  • Table 31. Global Short-acting EPO Drugs Sales Share by Type (2018-2023)
  • Table 32. Global Short-acting EPO Drugs Sales Share by Type (2024-2029)
  • Table 33. Global Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 34. Global Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 35. Global Short-acting EPO Drugs Revenue Share by Type (2018-2023)
  • Table 36. Global Short-acting EPO Drugs Revenue Share by Type (2024-2029)
  • Table 37. Short-acting EPO Drugs Price by Type (2018-2023) & (US$/Unit)
  • Table 38. Global Short-acting EPO Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
  • Table 39. Global Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
  • Table 40. Global Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
  • Table 41. Global Short-acting EPO Drugs Sales Share by Application (2018-2023)
  • Table 42. Global Short-acting EPO Drugs Sales Share by Application (2024-2029)
  • Table 43. Global Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 44. Global Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 45. Global Short-acting EPO Drugs Revenue Share by Application (2018-2023)
  • Table 46. Global Short-acting EPO Drugs Revenue Share by Application (2024-2029)
  • Table 47. Short-acting EPO Drugs Price by Application (2018-2023) & (US$/Unit)
  • Table 48. Global Short-acting EPO Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
  • Table 49. US & Canada Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
  • Table 50. US & Canada Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
  • Table 51. US & Canada Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 52. US & Canada Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 53. US & Canada Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
  • Table 54. US & Canada Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
  • Table 55. US & Canada Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 56. US & Canada Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 57. US & Canada Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 58. US & Canada Short-acting EPO Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 59. US & Canada Short-acting EPO Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 60. US & Canada Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)
  • Table 61. US & Canada Short-acting EPO Drugs Sales by Country (2024-2029) & (K Units)
  • Table 62. Europe Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
  • Table 63. Europe Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
  • Table 64. Europe Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 65. Europe Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 66. Europe Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
  • Table 67. Europe Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
  • Table 68. Europe Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 69. Europe Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 70. Europe Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 71. Europe Short-acting EPO Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 72. Europe Short-acting EPO Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 73. Europe Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)
  • Table 74. Europe Short-acting EPO Drugs Sales by Country (2024-2029) & (K Units)
  • Table 75. China Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
  • Table 76. China Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
  • Table 77. China Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 78. China Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 79. China Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
  • Table 80. China Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
  • Table 81. China Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 82. China Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 83. Asia Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
  • Table 84. Asia Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
  • Table 85. Asia Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 86. Asia Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 87. Asia Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
  • Table 88. Asia Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
  • Table 89. Asia Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 90. Asia Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 91. Asia Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 92. Asia Short-acting EPO Drugs Revenue by Region (2018-2023) & (US$ Million)
  • Table 93. Asia Short-acting EPO Drugs Revenue by Region (2024-2029) & (US$ Million)
  • Table 94. Asia Short-acting EPO Drugs Sales by Region (2018-2023) & (K Units)
  • Table 95. Asia Short-acting EPO Drugs Sales by Region (2024-2029) & (K Units)
  • Table 96. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Type (2018-2023) & (K Units)
  • Table 97. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Type (2024-2029) & (K Units)
  • Table 98. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 99. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 100. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Application (2018-2023) & (K Units)
  • Table 101. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Application (2024-2029) & (K Units)
  • Table 102. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 103. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 104. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 105. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 106. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 107. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country (2018-2023) & (K Units)
  • Table 108. Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country (2024-2029) & (K Units)
  • Table 109. Amgen Company Information
  • Table 110. Amgen Description and Major Businesses
  • Table 111. Amgen Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 112. Amgen Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 113. Amgen Recent Developments
  • Table 114. Johnson & Johnson Company Information
  • Table 115. Johnson & Johnson Description and Major Businesses
  • Table 116. Johnson & Johnson Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 117. Johnson & Johnson Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 118. Johnson & Johnson Recent Developments
  • Table 119. Roche Company Information
  • Table 120. Roche Description and Major Businesses
  • Table 121. Roche Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 122. Roche Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 123. Roche Recent Developments
  • Table 124. Kyowa Kirin Company Information
  • Table 125. Kyowa Kirin Description and Major Businesses
  • Table 126. Kyowa Kirin Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 127. Kyowa Kirin Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 128. Kyowa Kirin Recent Developments
  • Table 129. LG Chem Company Information
  • Table 130. LG Chem Description and Major Businesses
  • Table 131. LG Chem Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 132. LG Chem Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 133. LG Chem Recent Developments
  • Table 134. Daewoong Pharmaceutical Company Information
  • Table 135. Daewoong Pharmaceutical Description and Major Businesses
  • Table 136. Daewoong Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 137. Daewoong Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 138. Daewoong Pharmaceutical Recent Developments
  • Table 139. Wockhardt Company Information
  • Table 140. Wockhardt Description and Major Businesses
  • Table 141. Wockhardt Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 142. Wockhardt Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 143. Wockhardt Recent Developments
  • Table 144. CJ Healthcare Company Information
  • Table 145. CJ Healthcare Description and Major Businesses
  • Table 146. CJ Healthcare Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 147. CJ Healthcare Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 148. CJ Healthcare Recent Developments
  • Table 149. 3SBio Company Information
  • Table 150. 3SBio Description and Major Businesses
  • Table 151. 3SBio Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 152. 3SBio Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 153. 3SBio Recent Developments
  • Table 154. Kexing Biopharm Company Information
  • Table 155. Kexing Biopharm Description and Major Businesses
  • Table 156. Kexing Biopharm Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 157. Kexing Biopharm Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 158. Kexing Biopharm Recent Developments
  • Table 159. Harbin Pharmaceutical Group Company Information
  • Table 160. Harbin Pharmaceutical Group Description and Major Businesses
  • Table 161. Harbin Pharmaceutical Group Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 162. Harbin Pharmaceutical Group Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 163. Harbin Pharmaceutical Group Recent Developments
  • Table 164. Beijing Four Rings Bio-Pharmaceutical Company Information
  • Table 165. Beijing Four Rings Bio-Pharmaceutical Description and Major Businesses
  • Table 166. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 167. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 168. Beijing Four Rings Bio-Pharmaceutical Recent Developments
  • Table 169. Key Raw Materials Lists
  • Table 170. Raw Materials Key Suppliers Lists
  • Table 171. Short-acting EPO Drugs Distributors List
  • Table 172. Short-acting EPO Drugs Customers List
  • Table 173. Short-acting EPO Drugs Market Trends
  • Table 174. Short-acting EPO Drugs Market Drivers
  • Table 175. Short-acting EPO Drugs Market Challenges
  • Table 176. Short-acting EPO Drugs Market Restraints
  • Table 177. Research Programs/Design for This Report
  • Table 178. Key Data Information from Secondary Sources
  • Table 179. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Short-acting EPO Drugs Product Picture
  • Figure 2. Global Short-acting EPO Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Short-acting EPO Drugs Market Share by Type in 2022 & 2029
  • Figure 4. Epoetin-alfa Product Picture
  • Figure 5. Epoetin-beta Product Picture
  • Figure 6. Darbepoetin-alfa Product Picture
  • Figure 7. Others Product Picture
  • Figure 8. Global Short-acting EPO Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 9. Global Short-acting EPO Drugs Market Share by Application in 2022 & 2029
  • Figure 10. Anemia
  • Figure 11. Kidney Disorders
  • Figure 12. Others
  • Figure 13. Short-acting EPO Drugs Report Years Considered
  • Figure 14. Global Short-acting EPO Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
  • Figure 15. Global Short-acting EPO Drugs Revenue 2018-2029 (US$ Million)
  • Figure 16. Global Short-acting EPO Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
  • Figure 17. Global Short-acting EPO Drugs Revenue Market Share by Region (2018-2029)
  • Figure 18. Global Short-acting EPO Drugs Sales 2018-2029 ((K Units)
  • Figure 19. Global Short-acting EPO Drugs Sales Market Share by Region (2018-2029)
  • Figure 20. US & Canada Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 21. US & Canada Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 22. Europe Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 23. Europe Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 24. China Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 25. China Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 26. Asia (excluding China) Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 27. Asia (excluding China) Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 28. Middle East, Africa and Latin America Short-acting EPO Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 29. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 30. The Short-acting EPO Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
  • Figure 31. The Top 5 and 10 Largest Manufacturers of Short-acting EPO Drugs in the World: Market Share by Short-acting EPO Drugs Revenue in 2022
  • Figure 32. Global Short-acting EPO Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 33. Global Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • Figure 34. Global Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • Figure 35. Global Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • Figure 36. Global Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • Figure 37. US & Canada Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • Figure 38. US & Canada Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • Figure 39. US & Canada Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • Figure 40. US & Canada Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • Figure 41. US & Canada Short-acting EPO Drugs Revenue Share by Country (2018-2029)
  • Figure 42. US & Canada Short-acting EPO Drugs Sales Share by Country (2018-2029)
  • Figure 43. U.S. Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 44. Canada Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 45. Europe Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • Figure 46. Europe Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • Figure 47. Europe Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • Figure 48. Europe Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • Figure 49. Europe Short-acting EPO Drugs Revenue Share by Country (2018-2029)
  • Figure 50. Europe Short-acting EPO Drugs Sales Share by Country (2018-2029)
  • Figure 51. Germany Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 52. France Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 53. U.K. Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 54. Italy Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 55. Russia Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 56. China Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • Figure 57. China Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • Figure 58. China Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • Figure 59. China Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • Figure 60. Asia Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • Figure 61. Asia Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • Figure 62. Asia Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • Figure 63. Asia Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • Figure 64. Asia Short-acting EPO Drugs Revenue Share by Region (2018-2029)
  • Figure 65. Asia Short-acting EPO Drugs Sales Share by Region (2018-2029)
  • Figure 66. Japan Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 67. South Korea Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 68. China Taiwan Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 69. Southeast Asia Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 70. India Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 71. Middle East, Africa and Latin America Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • Figure 72. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • Figure 73. Middle East, Africa and Latin America Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • Figure 74. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • Figure 75. Middle East, Africa and Latin America Short-acting EPO Drugs Revenue Share by Country (2018-2029)
  • Figure 76. Middle East, Africa and Latin America Short-acting EPO Drugs Sales Share by Country (2018-2029)
  • Figure 77. Brazil Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 78. Mexico Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 79. Turkey Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 80. Israel Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 81. GCC Countries Short-acting EPO Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 82. Short-acting EPO Drugs Value Chain
  • Figure 83. Short-acting EPO Drugs Production Process
  • Figure 84. Channels of Distribution
  • Figure 85. Distributors Profiles
  • Figure 86. Bottom-up and Top-down Approaches for This Report
  • Figure 87. Data Triangulation
  • Figure 88. Key Executives Interviewed
目次

This research report focuses on the Short-acting EPO Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Short-acting EPO Drugs Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Short-acting EPO Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
    • 1.2.2 Epoetin-alfa
    • 1.2.3 Epoetin-beta
    • 1.2.4 Darbepoetin-alfa
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Short-acting EPO Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
    • 1.3.2 Anemia
    • 1.3.3 Kidney Disorders
    • 1.3.4 Others
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Executive Summary

  • 2.1 Global Short-acting EPO Drugs Sales Estimates and Forecasts 2018-2029
  • 2.2 Global Short-acting EPO Drugs Revenue by Region
    • 2.2.1 Global Short-acting EPO Drugs Revenue by Region: 2018 VS 2022 VS 2029
    • 2.2.2 Global Short-acting EPO Drugs Revenue by Region (2018-2023)
    • 2.2.3 Global Short-acting EPO Drugs Revenue by Region (2024-2029)
    • 2.2.4 Global Short-acting EPO Drugs Revenue Market Share by Region (2018-2029)
  • 2.3 Global Short-acting EPO Drugs Sales Estimates and Forecasts 2018-2029
  • 2.4 Global Short-acting EPO Drugs Sales by Region
    • 2.4.1 Global Short-acting EPO Drugs Sales by Region: 2018 VS 2022 VS 2029
    • 2.4.2 Global Short-acting EPO Drugs Sales by Region (2018-2023)
    • 2.4.3 Global Short-acting EPO Drugs Sales by Region (2024-2029)
    • 2.4.4 Global Short-acting EPO Drugs Sales Market Share by Region (2018-2029)
  • 2.5 US & Canada
  • 2.6 Europe
  • 2.7 China
  • 2.8 Asia (excluding China)
  • 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

  • 3.1 Global Short-acting EPO Drugs Sales by Manufacturers
    • 3.1.1 Global Short-acting EPO Drugs Sales by Manufacturers (2018-2023)
    • 3.1.2 Global Short-acting EPO Drugs Sales Market Share by Manufacturers (2018-2023)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Short-acting EPO Drugs in 2022
  • 3.2 Global Short-acting EPO Drugs Revenue by Manufacturers
    • 3.2.1 Global Short-acting EPO Drugs Revenue by Manufacturers (2018-2023)
    • 3.2.2 Global Short-acting EPO Drugs Revenue Market Share by Manufacturers (2018-2023)
    • 3.2.3 Global Top 10 and Top 5 Companies by Short-acting EPO Drugs Revenue in 2022
  • 3.3 Global Key Players of Short-acting EPO Drugs, Industry Ranking, 2021 VS 2022 VS 2023
  • 3.4 Global Short-acting EPO Drugs Sales Price by Manufacturers
  • 3.5 Analysis of Competitive Landscape
    • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.5.2 Global Short-acting EPO Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.6 Global Key Manufacturers of Short-acting EPO Drugs, Manufacturing Base Distribution and Headquarters
  • 3.7 Global Key Manufacturers of Short-acting EPO Drugs, Product Offered and Application
  • 3.8 Global Key Manufacturers of Short-acting EPO Drugs, Date of Enter into This Industry
  • 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Short-acting EPO Drugs Sales by Type
    • 4.1.1 Global Short-acting EPO Drugs Historical Sales by Type (2018-2023)
    • 4.1.2 Global Short-acting EPO Drugs Forecasted Sales by Type (2024-2029)
    • 4.1.3 Global Short-acting EPO Drugs Sales Market Share by Type (2018-2029)
  • 4.2 Global Short-acting EPO Drugs Revenue by Type
    • 4.2.1 Global Short-acting EPO Drugs Historical Revenue by Type (2018-2023)
    • 4.2.2 Global Short-acting EPO Drugs Forecasted Revenue by Type (2024-2029)
    • 4.2.3 Global Short-acting EPO Drugs Revenue Market Share by Type (2018-2029)
  • 4.3 Global Short-acting EPO Drugs Price by Type
    • 4.3.1 Global Short-acting EPO Drugs Price by Type (2018-2023)
    • 4.3.2 Global Short-acting EPO Drugs Price Forecast by Type (2024-2029)

5 Market Size by Application

  • 5.1 Global Short-acting EPO Drugs Sales by Application
    • 5.1.1 Global Short-acting EPO Drugs Historical Sales by Application (2018-2023)
    • 5.1.2 Global Short-acting EPO Drugs Forecasted Sales by Application (2024-2029)
    • 5.1.3 Global Short-acting EPO Drugs Sales Market Share by Application (2018-2029)
  • 5.2 Global Short-acting EPO Drugs Revenue by Application
    • 5.2.1 Global Short-acting EPO Drugs Historical Revenue by Application (2018-2023)
    • 5.2.2 Global Short-acting EPO Drugs Forecasted Revenue by Application (2024-2029)
    • 5.2.3 Global Short-acting EPO Drugs Revenue Market Share by Application (2018-2029)
  • 5.3 Global Short-acting EPO Drugs Price by Application
    • 5.3.1 Global Short-acting EPO Drugs Price by Application (2018-2023)
    • 5.3.2 Global Short-acting EPO Drugs Price Forecast by Application (2024-2029)

6 US & Canada

  • 6.1 US & Canada Short-acting EPO Drugs Market Size by Type
    • 6.1.1 US & Canada Short-acting EPO Drugs Sales by Type (2018-2029)
    • 6.1.2 US & Canada Short-acting EPO Drugs Revenue by Type (2018-2029)
  • 6.2 US & Canada Short-acting EPO Drugs Market Size by Application
    • 6.2.1 US & Canada Short-acting EPO Drugs Sales by Application (2018-2029)
    • 6.2.2 US & Canada Short-acting EPO Drugs Revenue by Application (2018-2029)
  • 6.3 US & Canada Short-acting EPO Drugs Market Size by Country
    • 6.3.1 US & Canada Short-acting EPO Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 6.3.2 US & Canada Short-acting EPO Drugs Sales by Country (2018-2029)
    • 6.3.3 US & Canada Short-acting EPO Drugs Revenue by Country (2018-2029)
    • 6.3.4 US
    • 6.3.5 Canada

7 Europe

  • 7.1 Europe Short-acting EPO Drugs Market Size by Type
    • 7.1.1 Europe Short-acting EPO Drugs Sales by Type (2018-2029)
    • 7.1.2 Europe Short-acting EPO Drugs Revenue by Type (2018-2029)
  • 7.2 Europe Short-acting EPO Drugs Market Size by Application
    • 7.2.1 Europe Short-acting EPO Drugs Sales by Application (2018-2029)
    • 7.2.2 Europe Short-acting EPO Drugs Revenue by Application (2018-2029)
  • 7.3 Europe Short-acting EPO Drugs Market Size by Country
    • 7.3.1 Europe Short-acting EPO Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 7.3.2 Europe Short-acting EPO Drugs Sales by Country (2018-2029)
    • 7.3.3 Europe Short-acting EPO Drugs Revenue by Country (2018-2029)
    • 7.3.4 Germany
    • 7.3.5 France
    • 7.3.6 U.K.
    • 7.3.7 Italy
    • 7.3.8 Russia

8 China

  • 8.1 China Short-acting EPO Drugs Market Size
    • 8.1.1 China Short-acting EPO Drugs Sales (2018-2029)
    • 8.1.2 China Short-acting EPO Drugs Revenue (2018-2029)
  • 8.2 China Short-acting EPO Drugs Market Size by Application
    • 8.2.1 China Short-acting EPO Drugs Sales by Application (2018-2029)
    • 8.2.2 China Short-acting EPO Drugs Revenue by Application (2018-2029)

9 Asia (excluding China)

  • 9.1 Asia Short-acting EPO Drugs Market Size by Type
    • 9.1.1 Asia Short-acting EPO Drugs Sales by Type (2018-2029)
    • 9.1.2 Asia Short-acting EPO Drugs Revenue by Type (2018-2029)
  • 9.2 Asia Short-acting EPO Drugs Market Size by Application
    • 9.2.1 Asia Short-acting EPO Drugs Sales by Application (2018-2029)
    • 9.2.2 Asia Short-acting EPO Drugs Revenue by Application (2018-2029)
  • 9.3 Asia Short-acting EPO Drugs Sales by Region
    • 9.3.1 Asia Short-acting EPO Drugs Revenue by Region: 2018 VS 2022 VS 2029
    • 9.3.2 Asia Short-acting EPO Drugs Revenue by Region (2018-2029)
    • 9.3.3 Asia Short-acting EPO Drugs Sales by Region (2018-2029)
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 China Taiwan
    • 9.3.7 Southeast Asia
    • 9.3.8 India

10 Middle East, Africa and Latin America

  • 10.1 Middle East, Africa and Latin America Short-acting EPO Drugs Market Size by Type
    • 10.1.1 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Type (2018-2029)
    • 10.1.2 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Type (2018-2029)
  • 10.2 Middle East, Africa and Latin America Short-acting EPO Drugs Market Size by Application
    • 10.2.1 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Application (2018-2029)
    • 10.2.2 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Application (2018-2029)
  • 10.3 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country
    • 10.3.1 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 10.3.2 Middle East, Africa and Latin America Short-acting EPO Drugs Revenue by Country (2018-2029)
    • 10.3.3 Middle East, Africa and Latin America Short-acting EPO Drugs Sales by Country (2018-2029)
    • 10.3.4 Brazil
    • 10.3.5 Mexico
    • 10.3.6 Turkey
    • 10.3.7 Israel
    • 10.3.8 GCC Countries

11 Company Profiles

  • 11.1 Amgen
    • 11.1.1 Amgen Company Information
    • 11.1.2 Amgen Overview
    • 11.1.3 Amgen Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.1.4 Amgen Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Amgen Recent Developments
  • 11.2 Johnson & Johnson
    • 11.2.1 Johnson & Johnson Company Information
    • 11.2.2 Johnson & Johnson Overview
    • 11.2.3 Johnson & Johnson Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.2.4 Johnson & Johnson Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Johnson & Johnson Recent Developments
  • 11.3 Roche
    • 11.3.1 Roche Company Information
    • 11.3.2 Roche Overview
    • 11.3.3 Roche Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.3.4 Roche Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Roche Recent Developments
  • 11.4 Kyowa Kirin
    • 11.4.1 Kyowa Kirin Company Information
    • 11.4.2 Kyowa Kirin Overview
    • 11.4.3 Kyowa Kirin Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.4.4 Kyowa Kirin Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Kyowa Kirin Recent Developments
  • 11.5 LG Chem
    • 11.5.1 LG Chem Company Information
    • 11.5.2 LG Chem Overview
    • 11.5.3 LG Chem Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.5.4 LG Chem Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 LG Chem Recent Developments
  • 11.6 Daewoong Pharmaceutical
    • 11.6.1 Daewoong Pharmaceutical Company Information
    • 11.6.2 Daewoong Pharmaceutical Overview
    • 11.6.3 Daewoong Pharmaceutical Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.6.4 Daewoong Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Daewoong Pharmaceutical Recent Developments
  • 11.7 Wockhardt
    • 11.7.1 Wockhardt Company Information
    • 11.7.2 Wockhardt Overview
    • 11.7.3 Wockhardt Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.7.4 Wockhardt Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Wockhardt Recent Developments
  • 11.8 CJ Healthcare
    • 11.8.1 CJ Healthcare Company Information
    • 11.8.2 CJ Healthcare Overview
    • 11.8.3 CJ Healthcare Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.8.4 CJ Healthcare Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 CJ Healthcare Recent Developments
  • 11.9 3SBio
    • 11.9.1 3SBio Company Information
    • 11.9.2 3SBio Overview
    • 11.9.3 3SBio Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.9.4 3SBio Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.9.5 3SBio Recent Developments
  • 11.10 Kexing Biopharm
    • 11.10.1 Kexing Biopharm Company Information
    • 11.10.2 Kexing Biopharm Overview
    • 11.10.3 Kexing Biopharm Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.10.4 Kexing Biopharm Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.10.5 Kexing Biopharm Recent Developments
  • 11.11 Harbin Pharmaceutical Group
    • 11.11.1 Harbin Pharmaceutical Group Company Information
    • 11.11.2 Harbin Pharmaceutical Group Overview
    • 11.11.3 Harbin Pharmaceutical Group Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.11.4 Harbin Pharmaceutical Group Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.11.5 Harbin Pharmaceutical Group Recent Developments
  • 11.12 Beijing Four Rings Bio-Pharmaceutical
    • 11.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
    • 11.12.2 Beijing Four Rings Bio-Pharmaceutical Overview
    • 11.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Short-acting EPO Drugs Industry Chain Analysis
  • 12.2 Short-acting EPO Drugs Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Short-acting EPO Drugs Production Mode & Process
  • 12.4 Short-acting EPO Drugs Sales and Marketing
    • 12.4.1 Short-acting EPO Drugs Sales Channels
    • 12.4.2 Short-acting EPO Drugs Distributors
  • 12.5 Short-acting EPO Drugs Customers

13 Market Dynamics

  • 13.1 Short-acting EPO Drugs Industry Trends
  • 13.2 Short-acting EPO Drugs Market Drivers
  • 13.3 Short-acting EPO Drugs Market Challenges
  • 13.4 Short-acting EPO Drugs Market Restraints

14 Key Findings in The Global Short-acting EPO Drugs Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer